Pollow K, Kreienberg R, Di Pietro N
Abteilung für Experimentelle Endokrinologie, Universitätsfrauenklinik Johannes-Gutenberg-Universität Mainz, Federal Republic of Germany.
J Cancer Res Clin Oncol. 1989;115(4):397-9. doi: 10.1007/BF00400970.
Two micronized oral formulations of medroxyprogesterone acetate (MPA) (Farlutal and Clinovir) were compared in order to evaluate their relative bioavailability. Sixteen female patients with metastatic breast cancer were entered in a randomized cross-over study on 500-mg MPA tablets repeatedly administered (twice daily for 20 days). At the steady state, similar mean +/- SD serum levels of MPA were obtained (131 +/- 44 ng/ml for Farlutal and 136 +/- 45 ng/ml for Clinovir) and the two formulations proved to be bioequivalent (confidence interval at a significance level of 0.95 = 93%-107%).
比较了两种醋酸甲羟孕酮（MPA）的微粉化口服制剂（法乐通和环丙孕酮），以评估它们的相对生物利用度。16名转移性乳腺癌女性患者进入一项关于500毫克MPA片剂重复给药（每日两次，共20天）的随机交叉研究。在稳态时，获得了相似的MPA平均±标准差血清水平（法乐通为131±44纳克/毫升，环丙孕酮为136±45纳克/毫升），并且两种制剂被证明具有生物等效性（显著性水平为0.95时的置信区间=93%-107%）。
